Semmelweis University
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Semmelweis University, cardiovascular research focuses on atrial fibrillation and the prevention of stroke and systemic embolism. These studies are designed to test new blood-thinning strategies and compare their effectiveness and safety with established care.
- Preventing stroke in people with atrial fibrillation
- Evaluating safer alternatives to current anticoagulation treatments
- Studying benefit-risk balance in patients at high cardiovascular risk
This work supports better long-term protection for patients living with irregular heart rhythm and related clotting risks.
Digestive System Diseases
Research in digestive system diseases centers on ulcerative colitis, Crohn's disease, and related inflammatory bowel conditions. The trials aim to improve symptom control, bowel function, and overall disease management through new treatment options.
- Reducing bowel urgency and improving daily comfort
- Testing therapies for moderately to severely active ulcerative colitis
- Assessing treatments for Crohn's disease and long-term disease control
These studies explore whether newer therapies can offer stronger symptom relief and better intestinal healing for patients with chronic inflammation.
Hemic and Lymphatic Diseases
The Belgyogyaszati es Hematologiai Klinika is also active in hematology, with trials in multiple myeloma, diffuse large B-cell lymphoma, myelodysplastic syndrome, essential thrombocythaemia, and light-chain amyloidosis. The main goal is to evaluate new treatment combinations and improve disease response and survival.
- Studying therapies for relapsed or refractory multiple myeloma
- Investigating treatment options for lymphoma and chronic leukemia
- Assessing approaches for blood disorders such as MDS and essential thrombocythaemia
This portfolio reflects a strong focus on difficult-to-treat blood cancers and related disorders, with an emphasis on better response rates and longer survival.
Immune System Diseases
Trials in immune system diseases include hereditary angioedema and inflammatory conditions driven by immune dysfunction. The research is aimed at improving safety, reducing attacks or flares, and supporting more durable disease control.
- Evaluating long-term management for hereditary angioedema
- Testing new options for immune-mediated inflammation
- Measuring symptom improvement and treatment tolerability
These studies broaden the site’s work in immune-related disorders by exploring therapies that may offer more stable control over time.
Neoplasms
Oncology research at Semmelweis University includes hepatocellular carcinoma, advanced tumors, microsatellite instability-high colorectal cancer, and several hematologic malignancies. The trials are focused on testing new cancer therapies and improving outcomes after standard treatment.
- Assessing adjuvant treatment strategies after surgery or local therapy
- Comparing new immunotherapy approaches with established cancer care
- Studying survival, response, and disease control in advanced cancers
This area highlights a broad cancer research effort that includes both solid tumors and blood cancers, with a strong emphasis on effectiveness and long-term benefit.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 41 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 41 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Janssen Cilag International1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Semmelweis University
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 41 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 3 | Unknown | 2018-08-24 | 2021-06-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.